Trial
NCT05695391
A Phase 3 Study of the Safety and Efficacy of Coagulation Factor VIIa (Recombinant) for the Prevention of Excessive Bleeding in Patients With Congenital Hemophilia A or B With Inhibitors to Factor VIII or IX Undergoing Elective Major Surgical Procedures SCOPE HIM
Phase IIITERMINATEDOPERATIONALConfidence: HIGH
Sponsor
Laboratoire français de Fractionnement et de Biotechnologies
Collaborators
—
Condition
Hemophilia
Intervention
Coagulation Factor VIIa (Recombinant)
Why stopped
Feasibility considerations - extended timelines to complete recruitment
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2025-07-09